EXCLUSIVE LICENSE AGREEMENT FOR CK1d by and between AMGEN INC. and RBNC Therapeutics, Inc. Dated as of September 10, 2021Exclusive License Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This EXCLUSIVE LICENSE AGREEMENT FOR CK1d (this “Agreement”) is entered into as of September 10, 2021 (the “Execution Date”) by and between AMGEN INC. (“AMGEN”), and RBNC Therapeutics, Inc. (“RBNC”). RBNC and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This License Agreement is effective as of November 23, 2015 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and BLACKTHORN THERAPEUTICS, INC. (“Licensee”), a Delaware corporation located at 329 Oyster Point Blvd, South San Francisco, 94080.
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between AMGEN INC. and RBNC THERAPEUTICS, INC. Dated as of September 10, 2021Research Collaboration and License Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of September 10, 2021 (the “Execution Date”) is by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320, USA (“Amgen”) and RBNC Therapeutics, Inc., a Delaware corporation having an address at 1700 Owens Street, #535, San Francisco, California 94158, USA (“RBNC”). Amgen and RBNC are each hereafter referred to individually as a “Party” and together as the “Parties”.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (“Amendment”) is entered into effective as of November 13, 2017 and is made to the EXCLUSIVE LICENSE AGREEMENT dated November 23, 2015 (the “License Agreement”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and BLACKTHORN THERAPEUTICS, INC., a Delaware corporation (“Licensee”). Capitalized terms used but not defined herein shall have the same meanings set forth in the Agreement.
LICENSE AGREEMENTLicense Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”) is entered into as of this 15th day of June, 2020 (the “Effective Date”), by and between Syllable Life Sciences, Inc., a corporation existing under the laws of Delaware, having a place of business at c/o Cambridge Innovation Center, 1 Broadway, 14th floor, Cambridge, MA 02142 (“Syllable”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727E, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO LICENSE AGREEMENT (“Amendment No. 1”) is effective March 31, 2021 (the “Amendment No. 1 Effective Date”) and is made by and between Syllable Life Sciences, Inc. (“Syllable”), and the President and Fellows of Harvard College, (“Harvard”). This Amendment No. 1 shall serve as an amendment to that certain License Agreement dated June 15, 2020 by and between the parties (the “Agreement”). Except as expressly modified hereby, the Agreement shall continue in full force according to its terms. Capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the same meaning as set forth in the Agreement.
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 14th, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment (“Amendment”) is entered into effective as of April 9, 2019 and is made to the EXCLUSIVE LICENSE AGREEMENT dated November 23, 2015 as amended on November 13, 2017 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI“), and BLACKTHORN THERAPEUTICS, NC., a Delaware corporation (“Licensee”).
